Liposomal Irinotecan for Malignant Ascites
Part of Cancer clinical trials.
This trial tests a drug called liposomal irinotecan, given alone or with other medications, to treat fluid buildup in the belly caused by digestive system cancers. It's for people who have already tried standard treatments without success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed digestive system cancer that has spread to the belly and caused moderate to large fluid buildup (ascites).
- You have tried at least one prior treatment for your cancer or for the fluid buildup.
- You are able to take care of yourself most of the day (ECOG score 0-2).
- Your major organs, like your liver, kidneys, and bone marrow, are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests three drugs (bevacizumab, serplulimab, and rmhTNF-NC) given together to treat fluid buildup in the belly caused by digestive system cancers. It’s for people whose ascites has not improved after standard treatments.
This trial tests a new version of the chemotherapy drug irinotecan (called liposomal irinotecan) combined with bevacizumab, a targeted therapy, for people with colorectal cancer that has spread and has stopped responding to irinotecan. The goal is to see if this combination can control the tumor better.
This trial tests a new chemotherapy drug called liposomal irinotecan as a second treatment for metastatic colorectal cancer (cancer that has spread beyond the colon or rectum). You would be eligible if your cancer progressed after your first chemotherapy treatment and you're in good enough health to receive more treatment.
This trial tests a new combination therapy using liposomal irinotecan for people with advanced stomach or gastroesophageal junction cancer that has stopped responding to first-line treatment. It may be an option if you are looking for a second-line therapy.
This trial tests a new form of the chemotherapy drug irinotecan (called liposomal irinotecan) for people with advanced, aggressive neuroendocrine cancer that has not responded to at least one prior treatment. The goal is to see if this version of the drug works better or has fewer side effects.
This trial tests a new form of chemotherapy (liposomal irinotecan) combined with two standard drugs (5-FU and leucovorin) and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this combination shrinks tumors and helps people live longer.
Hear when a new Malignant Ascites trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.